Maolac uses a proteomics discovery platform and computational biology to identify and extract functional proteins from bovine colostrum and plant-based sources, building a library of over 1,500 bioactive proteins found in human breast milk. The company found bovine colostrum contains more than 400 homolog proteins with over 95% biosimilarity to human breast milk and formulates a white powdered milk protein mixture that digests similarly to breast milk and can be added to cooked foods. Maolac says its mixtures produce higher overall efficacy at lower dosages and plans to price competitively relative to existing ingredients (competitors charge about $500/kg). The company is pre-revenue and is working on a first product line of anti-inflammatory aids: one for athletes to reduce muscle strain and speed recovery, and one to improve elderly mobility, with products expected to hit the market in 2023. Maolac is building a pilot facility with ~100 kg/month small‑scale production capacity, preparing analytics and samples for customers and clinical trials, and plans to expand its 12‑person team. It is also pursuing regulatory approval in the U.S. and Europe and is in discussions with food, supplement and dairy companies globally.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2022